Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Julia Driessen; Marie José Kersten; Lydia Visser; Anke van den Berg; Sanne H Tonino; Josée M Zijlstra; Pieternella J Lugtenburg; Franck Morschhauser; Martin Hutchings; Sandy Amorim; Thomas Gastinne; Marcel Nijland; Gerben J C Zwezerijnen; Ronald Boellaard; Henrica C W de Vet; Anne I J Arens; Roelf Valkema; Roberto D K Liu; Esther E E Drees; Daphne de Jong; Wouter J Plattel; Arjan Diepstra; HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC)

doi:10.1038/s41375-022-01717-8

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Julia Driessen, Marie José Kersten^*, Lydia Visser, Anke van den Berg, Sanne H Tonino, Josée M Zijlstra, Pieternella J Lugtenburg, Franck Morschhauser, Martin Hutchings, Sandy Amorim, Thomas Gastinne, Marcel Nijland, Gerben J C Zwezerijnen, Ronald Boellaard, Henrica C W de Vet, Anne I J Arens, Roelf Valkema, Roberto D K Liu, Esther E E Drees, Daphne de JongWouter J Plattel, Arjan Diepstra^*, HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC)

^*Corresponding author for this work

Department of Haematology

20 Citations (Scopus)

Abstract

Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67-88%) and the overall survival was 95% (90-100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.

Original language	English
Journal	Leukemia
Volume	36
Issue number	12
Pages (from-to)	2853-2862
Number of pages	10
ISSN	0887-6924
DOIs	https://doi.org/10.1038/s41375-022-01717-8
Publication status	Published - Dec 2022

Keywords

Brentuximab Vedotin
Hodgkin Disease/diagnostic imaging
Humans
Immunoconjugates/therapeutic use
Neoplasm Recurrence, Local/diagnostic imaging
Positron-Emission Tomography
Prognosis
Prospective Studies
Stem Cell Transplantation
Vitamin D/therapeutic use

Access to Document

10.1038/s41375-022-01717-8

Cite this

Driessen, J., Kersten, M. J., Visser, L., van den Berg, A., Tonino, S. H., Zijlstra, J. M., Lugtenburg, P. J., Morschhauser, F., Hutchings, M., Amorim, S., Gastinne, T., Nijland, M., Zwezerijnen, G. J. C., Boellaard, R., de Vet, H. C. W., Arens, A. I. J., Valkema, R., Liu, R. D. K., Drees, E. E. E., ... HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC) (2022). Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP. Leukemia, 36(12), 2853-2862. https://doi.org/10.1038/s41375-022-01717-8

Driessen, J, Kersten, MJ, Visser, L, van den Berg, A, Tonino, SH, Zijlstra, JM, Lugtenburg, PJ, Morschhauser, F, Hutchings, M, Amorim, S, Gastinne, T, Nijland, M, Zwezerijnen, GJC, Boellaard, R, de Vet, HCW, Arens, AIJ, Valkema, R, Liu, RDK, Drees, EEE, de Jong, D, Plattel, WJ, Diepstra, A & HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC) 2022, 'Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP', Leukemia, vol. 36, no. 12, pp. 2853-2862. https://doi.org/10.1038/s41375-022-01717-8

@article{605426260b5c45eda14dd038e136f54d,

title = "Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP",

abstract = "Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77\% (95\% CI: 67-88\%) and the overall survival was 95\% (90-100\%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.",

keywords = "Brentuximab Vedotin, Hodgkin Disease/diagnostic imaging, Humans, Immunoconjugates/therapeutic use, Neoplasm Recurrence, Local/diagnostic imaging, Positron-Emission Tomography, Prognosis, Prospective Studies, Stem Cell Transplantation, Vitamin D/therapeutic use",

author = "Julia Driessen and Kersten, \{Marie Jos{\'e}\} and Lydia Visser and \{van den Berg\}, Anke and Tonino, \{Sanne H\} and Zijlstra, \{Jos{\'e}e M\} and Lugtenburg, \{Pieternella J\} and Franck Morschhauser and Martin Hutchings and Sandy Amorim and Thomas Gastinne and Marcel Nijland and Zwezerijnen, \{Gerben J C\} and Ronald Boellaard and \{de Vet\}, \{Henrica C W\} and Arens, \{Anne I J\} and Roelf Valkema and Liu, \{Roberto D K\} and Drees, \{Esther E E\} and \{de Jong\}, Daphne and Plattel, \{Wouter J\} and Arjan Diepstra and \{HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC)\}",

note = "{\textcopyright} 2022. The Author(s), under exclusive licence to Springer Nature Limited.",

year = "2022",

month = dec,

doi = "10.1038/s41375-022-01717-8",

language = "English",

volume = "36",

pages = "2853--2862",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "12",

}

TY - JOUR

T1 - Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

AU - Driessen, Julia

AU - Kersten, Marie José

AU - Visser, Lydia

AU - van den Berg, Anke

AU - Tonino, Sanne H

AU - Zijlstra, Josée M

AU - Lugtenburg, Pieternella J

AU - Morschhauser, Franck

AU - Hutchings, Martin

AU - Amorim, Sandy

AU - Gastinne, Thomas

AU - Nijland, Marcel

AU - Zwezerijnen, Gerben J C

AU - Boellaard, Ronald

AU - de Vet, Henrica C W

AU - Arens, Anne I J

AU - Valkema, Roelf

AU - Liu, Roberto D K

AU - Drees, Esther E E

AU - de Jong, Daphne

AU - Plattel, Wouter J

AU - Diepstra, Arjan

AU - HOVON Lunenburg Lymphoma Phase I/II Consortium (LLPC)

PY - 2022/12

Y1 - 2022/12

N2 - Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67-88%) and the overall survival was 95% (90-100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.

AB - Risk-stratified treatment strategies have the potential to increase survival and lower toxicity in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) patients. This study investigated the prognostic value of serum (s)TARC, vitamin D and lactate dehydrogenase (LDH), TARC immunohistochemistry and quantitative PET parameters in 65 R/R cHL patients who were treated with brentuximab vedotin (BV) and DHAP followed by autologous stem-cell transplantation (ASCT) within the Transplant BRaVE study (NCT02280993). At a median follow-up of 40 months, the 3-year progression free survival (PFS) was 77% (95% CI: 67-88%) and the overall survival was 95% (90-100%). Significant adverse prognostic markers for progression were weak/negative TARC staining of Hodgkin Reed-Sternberg cells in the baseline biopsy, and a high standard uptake value (SUV)mean or SUVpeak on the baseline PET scan. After one cycle of BV-DHAP, sTARC levels were strongly associated with the risk of progression using a cutoff of 500 pg/ml. On the pre-ASCT PET scan, SUVpeak was highly prognostic for progression post-ASCT. Vitamin D, LDH and metabolic tumor volume had low prognostic value. In conclusion, we established the prognostic impact of sTARC, TARC staining, and quantitative PET parameters for R/R cHL, allowing the use of these parameters in prospective risk-stratified clinical trials. Trial registration: NCT02280993.

KW - Brentuximab Vedotin

KW - Hodgkin Disease/diagnostic imaging

KW - Humans

KW - Immunoconjugates/therapeutic use

KW - Neoplasm Recurrence, Local/diagnostic imaging

KW - Positron-Emission Tomography

KW - Prognosis

KW - Prospective Studies

KW - Stem Cell Transplantation

KW - Vitamin D/therapeutic use

UR - https://www.scopus.com/pages/publications/85140062604

U2 - 10.1038/s41375-022-01717-8

DO - 10.1038/s41375-022-01717-8

M3 - Journal article

C2 - 36241696

SN - 0887-6924

VL - 36

SP - 2853

EP - 2862

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Prognostic value of TARC and quantitative PET parameters in relapsed or refractory Hodgkin lymphoma patients treated with brentuximab vedotin and DHAP

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this